Ultrasmall Renally Clearable Silica Nanoparticles Target Prostate Cancer.

Abstract

Although important advances have been achieved in the development of radiolabeled prostate-specific membrane antigen (PSMA)-targeting ligand constructs for both diagnosis and therapy of prostate cancer (PCa) over the past decade, challenges related to off-target effects and limited treatment responses persist. In this study, which builds upon the successful clinical translation of a series of ultrasmall, dye-encapsulating core-shell silica nanoparticles, or Cornell Prime Dots (C' dots), for cancer management, we sought to address these limitations by designing a dual-modality, PSMA-targeting platform that evades undesirable accumulations in the salivary glands, kidneys, and reticuloendothelial system, while exhibiting bulk renal clearance. This versatile PCa-targeted particle imaging probe offers significant clinical potential to improve future theranostic applications in a variety of patient care settings.

• Authors: Feng Chen, Kai Ma, Li Zhang, Brian Madajewski, Melik Z Turker, Fabio Gallazzi, Kiara Cruickshank, Xiuli Zhang, Pocharapong Jenjitranant, Karim A Touijer, Thomas P Quinn, Pat Zanzonico, Ulrich Wiesner, Michelle S Bradbury
• Journal: ACS applied materials & interfaces (ACS Appl Mater Interfaces) Vol. 11 Issue 47 Pg. 43879-43887 (Nov 27 2019) ISSN: 1944-8252 [Electronic] United States
• PMID: 31675204 (Publication Type: Journal Article)

Chemical References

• Silicon Dioxide
• Prostate-Specific Antigen

Topics

• Animals
• Humans
• Kidney (metabolism)
• Liver (metabolism)
• Male
• Mice
• Mice, Inbred NOD
• Nanoparticles (chemistry, metabolism)
• Positron-Emission Tomography (instrumentation)
• Prostate-Specific Antigen (antagonists & inhibitors, metabolism)
• Prostatic Neoplasms (diagnostic imaging, metabolism)
• Silicon Dioxide (chemistry, metabolism)
• Theranostic Nanomedicine